Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 6/2008

01-06-2008 | Review

Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses

Author: N. Singh

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2008

Login to get access

Abstract

Immune regulatory pathways involving the newly discovered T regulatory (Treg) and Th17 cells are amongst the principal targets of immunosuppressive agents employed in transplant recipients and key mediators of host inflammatory responses in fungal infections. These novel signaling pathways, in concert with or independent of Th1/Th2 responses, have potentially important implications for yielding valuable insights into the pathogenesis of immune reconstitution syndrome (IRS) in transplant recipients, for aiding the diagnosis of this entity, and for achieving a balance of immune responses that enhance host immunity while curbing unfettered inflammation in IRS.
Literature
1.
Singh N, Perfect JR (2007) Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 7:395–401PubMedCrossRef
2.
Lortholary O, Fontanet A, Memain N et al (2005) Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 19:1043–1049PubMedCrossRef
3.
Shelburne SA, Hamill RJ, Rodriguez-Barradas MC et al (2002) Immune reconstitution inflammatory syndrome, emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 81:213–227PubMedCrossRef
4.
Casadevall A, Pirofski LA (2003) The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 1:17–24PubMedCrossRef
5.
Shelburne SA, Darcourt J, White C Jr et al (2005) The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 40:1045–1052CrossRef
6.
Hirsch HH, Kaufmann G, Sendi P et al (2004) Immune reconstitution in HIV-infected patients. Clin Infect Dis 38:1159–1166PubMedCrossRef
7.
Cheng VCC, Yuen KY, Wong SSY et al (2001) Immunorestitution disease in patients not infected with HIV. Eur J Clin Microbiol Infect Dis 20:402–406PubMedCrossRef
8.
Einsiedel L, Gordon DL, Dyer JR (2004) Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV seronegative woman. Clin Infect Dis 39:e78–e82PubMedCrossRef
9.
Clemons KV, Stevens DA (2001) Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy. Semin Respir Infect 16:60–66PubMedCrossRef
10.
Romani L, Pucetti P (2007) Controlling pathogenic inflammation to fungi. Expert Rev Anti Infect Ther 5:1007–1017PubMedCrossRef
11.
Cenci E, Perito S, Enssle KH et al (1997) Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun 65:564–570PubMed
12.
13.
Goriely S, Goldman M (2007) The interleukin-12 family: new players in transplantation immunity? Am J Transplant 7:278–284PubMedCrossRef
14.
Nelms K, Keegan A, Zamorano J et al (1999) The IL-4 receptor: signaling mechanisms and biologic functions. Ann Rev Immunol 17:701–738CrossRef
15.
Afzali B, Lombardi G, Lechler R, Lord G (2007) The role of T helper (TH17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 148:32–46PubMedCrossRef
16.
Mangan P, Harrington L, O’Quinn D et al (2006) Transforming growth factor-beta induces development of the T (H) 17 lineage. Nature 441:231–234PubMedCrossRef
17.
Cooke A (2006) Th17 cells in inflammatory conditions. Rev Diabetic Stud 372–375
18.
Bi Y, Guangwei L, Yang R (2007) Th17 cell induction and immune regulatory effects. J Cell Physiol 211:273–278PubMedCrossRef
19.
Schmidt-Weber C, Akdis M, Akdis C (2007) TH17 cells in the big picture of immunology. J Allergy Clin Immunol 120:247–254PubMedCrossRef
20.
Stockinger B, Veldhoen M (2007) Differentiation and function of Th17 T cells. Curr Opin Immunol 3:281–286CrossRef
21.
Bettelli E, Carrier Y, Gao W et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238PubMedCrossRef
22.
Veldhoen M, Hocking R, Atkins C et al (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de nova differentiation of IL-17-producing T cells. Immunity 24:179–189PubMedCrossRef
23.
Pyzik M, Piccirillo C (2007) TGF-beta 1 modulates FoxP3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukov Biol 82:335–346CrossRef
24.
Chen W, Jin W, Hardegen N et al (2003) Conversion of peripheral TGF-beta CD4+CD5-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 1875–1886
25.
Yagi H, Normura T, Nakamura K et al (2004) Crucial role of FoxP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 11:1643–1656CrossRef
26.
Sakaguchi S (2005) Naturally arising FoxP3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immun 6:345–354PubMedCrossRef
27.
Fontenot J, Gavin M, Rudensky A (2003) FoxP3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immun 4:330–336PubMedCrossRef
28.
Waldmann H, Graca L, Cobbold S et al (2004) Regulatory T cells and organ transplantation. Semin Immunol 16:119–126PubMedCrossRef
29.
de Kleer I, Wedderburn L, Taams L et al (2004) CD4+CD25bright regulatory T cells activity regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 10:6423–6435
30.
Matthys P, Vermeire K, Mitera T et al (1998) Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-gamma receptor-deficient mice. Eur J Immunol 28:2143–2151PubMedCrossRef
31.
Tang Q, Henriksen K, Bi M et al (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199:1455–1465PubMedCrossRef
32.
Long E, Wood K (2007) Understanding FOXP3: progress towards achieving transplantation tolerance. Transplantation 84:459–461PubMedCrossRef
33.
Gras J, Cornet A, Latinne D et al (2004) Evidence that Th1/Th2 immune deviation impacts on early graft acceptance after pediatric liver transplantation: results of immunological monitoring in 40 children. Am J Transplant 4:444CrossRef
34.
Saggi B, Fisher R, Naar J et al (1999) Intragraft cytokine expression in tolerant rat renal allografts with rapamycin and cyclosporin immunosuppression. Clin Transplant 13:90–97PubMedCrossRef
35.
Salama A, Najafian N, Clarkson M et al (2003) Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol 6:1643–1651CrossRef
36.
Graca L, Cobbold S, Waldmann H (2002) Identification of regulatory T cells in tolerated allografts. J Exp Med 195:1641PubMedCrossRef
37.
Bloom DD, Brahmbhatt R, Knechtle S (2007) Flow cytometric characterization regulatory T lymphocyte populations in renal transplant patients treated with Campath and tacrolimus. Presented at the American Transplant Congress, May 5–7, San Francisco, CA
38.
Lopez M, Clarkson M, Sayegh A et al (2006) A novel mechanism of action for anti-thymocyte globulin induction of CD4+CD25+FoxP3+ regulatory T cells. J Am Soc Nephrol 10:2644–2646
39.
Watanabe T, Masuyama J, Sohma Y et al (2006) CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 3:247–259CrossRef
40.
Karagiannidis C, Akdis M, Holopainen P et al (2004) Glucocorticoids up-regulate CAP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 114:1425–1433PubMedCrossRef
41.
Segundo D, Ruiz J, Izquierdo M et al (2006) Calcineurin inhibitors, but no rapamycin, reduce percentages of CD4+CD25+FoxP3+ Regulatory T cells in renal transplant recipients. Transplantation 82:550–557PubMedCrossRef
42.
Baan C, van der Mast B, Klepper M et al (2005) Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin of the induction of FoxP3 in human T Cells. Transplantation 80:110–117PubMedCrossRef
43.
Bensinger S, Walsh P, Zhang J (2004) Distinct IL-2 receptor signaling pattern in CD4+CD25+regulatory T cells. J Immunol 172:5287PubMed
44.
Fontenot J, Rasmussen J, Gavin M et al (2005) A function for interleukin 2 in FoxP3-expressing regulatory T cells. Nat Immunol 6:1142PubMedCrossRef
45.
Battaglia M, Stabilini A, Roncarolo M (2005) Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105:4743–4748PubMedCrossRef
46.
Nagai H, Guo J, Choi H et al (1995) Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 172:1554–1560PubMed
47.
Kawakami K (2004) Regulation by innate immune T lymphocytes in the host defense against pulmonary infection with Cryptococcus neoformans. Jpn J Infect Dis 57:137–145PubMed
48.
Decken K, Kohler G, Palmer-Lehmann K et al (1998) Interleukin-12 is essential for protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun 66:4994–5000PubMed
49.
Aguirre K, Havell EA, Gibson GW (1995) Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect Immun 63:1725–1731PubMed
50.
Vecchiarelli A, Retini C, Monari C et al (1996) Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 64:2846–2849PubMed
51.
Vecchiarelli A, Retini C, Pietrella D et al (1995) Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1β secretion from human monocytes. Infect Immun 63:2919–2923PubMed
52.
Rudner X, Happel K, Young E et al (2007) Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect Immun 75:3055–3061PubMedCrossRef
53.
Zelante T, De Luca A, Bonifazi P et al (2007) IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 37:2695–2706PubMedCrossRef
54.
Rogers PD, Pearson MM, Cleary JD et al (2002) Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis. J Antimicrob Chemotherap 50:811–817CrossRef
55.
Razonable RR, Henault M, Lee LN et al (2005) Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrob Ag Chemother 4:1617–1621CrossRef
56.
Shadkchan Y, Keisari Y, Segal E (2004) Cytokines in mice treated with amphotericin B-intralipid. Med Mycol 42:123–128PubMedCrossRef
57.
Hohl T, Feldmesser M, Perlin D et al (2007) Caspofungin modulates inflammatory responses to Aspergillus fumgiatus through stage-specific effects on fungal β-glucan exposure. Annual meeting of the Infectious Diseases Society of America, 4–7 October, San Diego, CA
58.
Wheeler RT, Fink GR (2006) A drug-sensitive genetic network masks fungi from the immune system. PLOS Pathogens 2:328–339CrossRef
59.
Lortholary O, Sitbon K, Dromer F et al (2005) Evidence for HIV and Cryptococcus neoformans interactions on the pro- and antiinflammatory responses in blood during AIDS-associated cryptococcosis. Clin Microbiol Infect 11:296–300PubMedCrossRef
60.
Singh N, Lortholary O, Alexander BD et al (2005) An “immune reconstitution syndrome”-like entity associated with Cryptococcus neoformans infections in organ transplant recipients. Clin Infect Dis 40:1756–1761PubMedCrossRef
61.
Breton G, Adle-Biassette H, Therby A et al (2006) Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS 20:119–121PubMedCrossRef
62.
Cheng VCC, Yuen KY, Chan WM et al (2000) Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 30:882–892PubMedCrossRef
63.
Miceli M, Maertens J, Buve K et al (2007) Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 110:112–120PubMedCrossRef
64.
Tang Q, Bluestone J (2006) Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 212:217–237PubMedCrossRef
65.
Tarbell K, Petit L, Zuo X et al (2007) Dendritic cell-expanded, islet-specific CD4+CD25+CD62L+regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 204:191–201PubMedCrossRef
66.
Tarbell K, Yamazaki S, Olson K et al (2004) CD25+CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 199:1467–1477PubMedCrossRef
67.
Ingram P, Howman R, Leahy M et al (2007) Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis 12:115–117CrossRef
Metadata
Title
Novel immune regulatory pathways and their role in immune reconstitution syndrome in organ transplant recipients with invasive mycoses
Author
N. Singh
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2008
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-008-0461-2

Other articles of this Issue 6/2008

European Journal of Clinical Microbiology & Infectious Diseases 6/2008 Go to the issue

Article

The association between past Chlamydia pneumoniae infection and markers of chronic inflammation in obese women

Article

Methicillin-resistant versus methicillin-sensitive Staphylococcus aureus infective endocarditis

Article

High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia

Article

A novel identification scheme for genus Mycobacterium, M. tuberculosis complex, and seven mycobacteria species of human clinical impact

Brief Report

Peak plasma rifampicin level in tuberculosis patients with slow culture conversion

Brief Report

A serosurvey of Anaplasma phagocytophilum in blood donors in Crete, Greece
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits